



Commissioner Máire GEORGHEGAN-QUINN

**European Forum for Industrial Biotechnology (EFIB) 2012
Swissôtel, Düsseldorf, Germany
17 October 2012 – 18:30**

Name of main contact person: [REDACTED], E2
Name of Cabinet Member: Patricia REILLY

PROGRAMME OF THE CONFERENCE

Programme of 17th of October 2012, first day of the European Forum for Industrial Biotechnology (EFIB) 2012, also see <http://www.efibforum.com/2012-agenda.aspx>.

Open plenary

08.00	Registration and Refreshments
09.00	Opening Plenary Session Chair: Lars Hansen, President - Europe, Novozymes
09.00 - 09.10	Introduction by the Chair of EuropaBio's Industrial Biotech Council Lars Hansen, President- Europe, Novozymes, Denmark
09.10 - 09.25	Thomas Rachel, Parliamentary State Secretary, Federal Ministry of Education & Research, Germany
09.25 - 09.35	Helmut Dockter, Deputy Minister, Ministry of Innovation, Science and Research of the State of North Rhine-Westphalia
09.35 - 09.50	The new EU Strategy Dr Rudolf Strohmeier, Deputy Director General, DG Research and Innovation, Biotechnologies, Agriculture, Food, European Commission, Belgium
09.50 - 10.05	Prof Dr Bernd Muller Rober, Germany Bioeconomy Council, Germany
10.05 - 10.20	The Biorefinery of the future Jeff Lutt, Chief Executive Officer & President, POET, USA
10.20 - 10.30	Q&A
10.30 - 11.00	Morning refreshments
	PARTNERSHIPS AND JV'S IN THE BIOBASED ECONOMY
11.00 - 11.25	Avantium & The Coca Cola Company's partnerships for the development of 100% biobased PEF bottles Tom van Aken, CEO, Avantium, The Netherlands & Dr Klaus Stadler, Director, Environment & Water Resources Europe, The Coca Cola Company -Europe Group, Germany

11.25 - 11.50	Commercialisation of sustainable solutions through strong alliances: Reverdia, powered by Roquette and DSM Christophe Rupp-Dahlem , ProgramsDirector Plant-based Chemistry, Roquette, France & Dr Will van den Tweel , General Manager, Reverdia, The Netherlands
11.50 - 12.15	Strategic collaboration in the development and commercialization of succinate olasticizers-a new family of renewable specialty plasticizers, inspired by nature Babette Pettersen, Senior VP Marketing & Sales, BIOAMBER , Belgium & Karsten Job, VP Polymer Additives, Lanxess, Germany
12.15 - 12.40	Ensuring feedstock flexibility for isobutene production, a platform molecule for chemical and fuel applications Marc Delcourt, CEO, Global Bioenergies S.A. , France & Dr Sean Simpson, Chief Scientific Officer/Founder, LanzaTech, New Zealand
12.40	Lunch will be served for all speakers and delegates

Afternoon tracks

	Policy & Strategy Strategies for Implementing the BBE	Innovation Track Innovation Showcase
14.00 - 14.10	Session Chair: Joanna DuPont Inglis, Director, Industrial Biotechnology, EUROPABIO, Belgium	Session Chair: Dr Manfred Kircher, Chairman of the Board, CLIB2021 - Cluster industrielle Biotechnologie, Germany
14.10 - 14.25	Dr Yvonne Armitage, IB Sector Expert & Knowledge Transfer Manager BIOSCIENCES KTN, UK	Toward the development of a fully consolidated bioprocess for ethanol production: Deinove, what's new? Michel Krel, Executive Vice President, BD , Deinove, France
14.25 - 14.40	Structuring the biobased economy in North-Western Europe in a globalising context Prof.dr.ir. Luuk A.M. van der Wielen, Director of BE-Basic, Department of Biotechnology, TU Delft, The Netherlands	P.I.V.E.R.T.: A French Private Public Partnership to develop the oilseed Biorefinery Jean François ROUS, Director of Innovation, SOFIPROTEOL
14.40 - 14.55	Cluster CLIB2021 accelerates open innovation towards unusual value chains in bioeconomy	Advances in Lignocellulosic Enzyme Technology: A Platform for Sustainable Biofuel Production

	Dr. Achim Marx, Chairman of the Board CLIB2021	Mr. Floris Luger, Vice President Business Development, DuPont Industrial Biosciences, The Netherlands
14.55 - 15.10	How to overcome hurdles for the bio-based economy Michael Carus, CEO, NOVA-INSTITUT GMBH, Germany	Bio-MTBE - how to reduce CO2 footprint in fuels with a well known premium gasoline component Dr. Oliver M. Busch, Strategic Research / AI-IM, Evonik Industries AG, Germany
15.10 - 15.40	Coffee break	Coffee break
15.40 - 15.55	The demo plant: a critical passage, at least recommended, in an innovation itinerary Yvon Le Hénaff, General Manager, ARD, France	The C1-technology platform for versatile, robust enzymes enabling a variety of second generation biofuels and chemicals processes Dr. Jan Wery, Science Director, Dyadic Netherlands, The Netherlands
15.55 - 16.10	Prospects of Bioeconomy in the Russian Federation Prof. Vladimir Popov, RUSSIAN ACADEMY OF SCIENCES, Russia	MicroBiOil®: Production of renewable biofuel Jose L. Adrio, Head of Bioindustrial Division, NEOL Biosolutions, Spain
16.10 - 16.25	Accelerating Innovation and Creating Sustainable Wealth through Bioeconomy Initiative Malaysia (BIM) Dr. Mohd Nazlee Kamal, CEO, MALAYSIAN BIOTECHNOLOGY CORPORATION SDN BHD, Malaysia	The role of SMEs in building up a sustainable, biobased economy Dr. Marc Struhalla, CEO, c-LEcta GmbH, Germany
	Finance Track Chair: Dr. Bernward Garthoff, State Representative for Biotechnology of the Federal State of North Rhine-Westphalia, BIO.NRW, Germany	

16.25 - 16.45	Financing of red and white biotech companies: a comparison Dr. David Karabelnik, Managing Partner, BRESLIN AG, Switzerland	Enzymatic biofilm removal, for food security and public health issues Benoît Duculot, Business Development - Director, S.A. REALCO NV, Belgium
16.45 - 17.05	Financing and support of new start-up companies in the bio-based economy by Founding Angels Dr. Gunter Festel, CFO, AUTO DISPLAY BIOTECH, Germany	Advanced Purification Technologies For Your Bio-Based Chemicals Thibault Lesaffre, Bioindustries Market Director, Novasep Process, France
17.05 - 17.25	The Industrial Biotech IPO Market - Trends and Drivers Maximilian Erb, Investment Manager, NRW.BANK, Germany	Rational design of microbes for competitive biotechnological processes Isabel Rocha, CSO, SilicoLife
17.25- 17.35	Q&A	Q&A

17.35 Close of conference day one and Grand Evening Reception

18.30 Policy keynote: Maire Geoghegan-Quinn, European Commission and Dr. Günther Horsetzky, Ministry for Economic Affairs of the State North-Rhine Westphalia, Germany will address delegates and speakers at the 2012 **Grand Drinks Reception**.

SPEECH FOR VIDEO-MESSAGE

- Ladies and gentlemen, while I cannot be with you in person tonight, I am delighted to say a few words at the occasion of this important conference. The EFIB 2012 touches on many subjects that are of direct relevance to our current activities, in particular the new Research and Innovation Framework Programme, Horizon 2020, and the European Bioeconomy Strategy.
- Industrial biotechnology has a strong innovation potential, which allows to reconcile long-term economic growth with Europe's ambition to move towards a low carbon economy by 2050. It can increase the competitiveness of European industries by providing more sustainable and resource efficient bio-based processes and generate economic growth by developing bio-based products that open entirely new markets.
- Industrial biotechnology can also contribute to addressing public concerns regarding the use of biomass for industrial and energy purposes by developing processes that facilitate the conversion of agricultural and forestry residues, as well as biowaste.
- As you may know, the European Commission has identified biotechnology as a Key Enabling Technology for the competitiveness of European industries. As a consequence, biotechnology-related activities are envisaged in all three priority areas of Horizon 2020. They will contribute to promoting scientific excellence, building competitive industries and addressing societal challenges.
- Research and innovation activities on industrial biotechnology and for the development of bio-based industries and their value chains will be predominantly funded under the Horizon 2020 section on the bioeconomy.
- In accordance with the European Bioeconomy Strategy, DG Research and Innovation is considering a possible Public Private Partnership on Bio-based Industries as an implementing tool for Horizon 2020. A PPP leverages

additional private investments and should be seen as a measure to enhance growth and creating jobs.

- For your benefit, a public consultation on the possible PPP on Bio-based Industries was launched on 21 September 2012. It is available on our RTD website and the website of "Your voice in Europe" until 14 December 2012.
- I encourage you to take part in this consultation and look forward to our future collaboration. Your contribution and commitment will be critical to enhancing the competitiveness of bio-based industries and building a bioeconomy in Europe.

IMPORTANT BACKGROUND and CONTEXTUAL INFORMATION

EFIB 2012 Conference

The European Forum for Industrial Biotechnology (EFIB) is an annual conference for the industrial biotechnology sectors that first took place in 2009. It has established itself as the leading European meeting place for science, industry, policymakers and investors. Last year's Forum attracted some 375 delegates from over 30 countries. The conference 2010 is operated by Smithers Rapra on behalf of EuropaBio, the European Association for Bioindustries, and is organised in partnership with CLIB 2021, an "Open Innovation Cluster" for bioeconomy with focus on industrial biotechnology.

For 2012, the programme will consist of two plenary sessions, CEO panel debate, advanced biofuels and marine biotech workshops as well as a presentation by the European Commissioner for Research, Innovation and science, Maire Geoghegan-Quinn at the Grand Evening Drinks Reception. General information about the event can be found at www.efibforum.com.

Scope of the intervention by Deputy Director-General R. Strohmeier

Deputy Director General R. Strohmeier was invited to be a speaker during the opening plenary of the EFIB 2012 Conference on 17th of October 2012. He will provide an update on the progress of European Commission initiatives in the field of research and innovation that are relevant to the industrial biotechnology sector, namely Horizon 2020, the two new PPP initiatives on Bio-based Industries and SPIRE. In particular he will:

- Introduce the European Framework Programme for Research and Innovation (Horizon 2020) with emphasis on the stronger integration of research and innovation activities at EU level into the "innovation chain" and new measures in support of SMEs.
- Underline the importance of biotechnology for the European economy and present relevant activities under the three objectives of Horizon 2020:
 - "Excellent Science", which supports bottom-up research in the area of biotechnology;
 - "Competitive Industries", in particular under the key enabling technology "Biotechnology";
 - "Better Society", in particular under the challenge "Food security, sustainable agriculture, marine and maritime research and the bio-economy" for industrial biotechnology, but also to some extent under the challenges "Health, demographic change and wellbeing", "Secure, clean and efficient energy" and "Climate action, resource efficiency and raw materials";
- Encourage industry's commitment to the envisaged PPP on Bio-based Industries and SPIRE that are currently being discussed between the Commission services and industries along the value chain. Stress in particular the importance of preparing strong proposals with well-defined goals and minimal overlap;
- Invite stakeholders to participate in Public Consultation on the PPP on Bio-based Industries that was launched on 21st September 2012;

- Emphasise the importance of industry participation in Horizon 2020 and in the potential PPPs, thus contributing to the recovery of the European economy and its future growth and competitiveness.